HIF-1alpha Therapeutic Stabilization for Ischemic Tissue Perfusion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hypoxia and ischemia, such as critical limb ischemia, are inadequate in promoting tissue perfusion and vascularization, leading to decreased tissue oxygen delivery and potential limb amputation.

Innovation Solution

A therapeutic comprising hypoxia-inducible factor-1 alpha (HIF-1α) is administered to promote vascularization, increase capillary density, and enhance tissue perfusion by stabilizing HIF-1α through proline-to-alanine substitutions, preventing ubiquitination and degradation, thereby maintaining its activity under normoxic conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HIF-1α is administered to promote vascularization and increase tissue perfusion, then tissue oxygen delivery is improved, but HIF-1α is rapidly degraded under normoxic conditions, reducing therapeutic efficacy

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidHIF-1α stability

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid sequence of HIF-1α through proline-to-alanine substitutions at positions 402 and 564. This chemical parameter change prevents hydroxylation and subsequent ubiquitination, thereby stabilizing the protein under normoxic conditions and extending its duration of action while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent addresses the short-lived nature of native HIF-1α by creating a stabilized variant that does not require continuous administration. The modified HIF-1α acts as a long-lasting therapeutic agent, eliminating the need for frequent dosing while maintaining reliable therapeutic effect.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If current treatments are used for hypoxia and ischemia, then treatment simplicity is maintained, but tissue perfusion and vascularization are inadequately promoted, leading to decreased tissue oxygen delivery

Engineering Contradiction:

Improvetissue oxygen deliveryVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts the key functional component (HIF-1α) from the complex physiological regulation system and delivers it directly as a therapeutic agent. This bypasses the need for complex pharmacological interventions while reliably improving tissue oxygen delivery through direct activation of angiogenic pathways.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The therapeutic effectively increases tissue perfusion, reduces tissue necrosis, and improves limb function in ischemic conditions by enhancing vascularization and collateral vessel formation, thereby preventing autoamputation and improving overall tissue health.

Implementation Method 1

preventing ubiquitination and degradation

Methodology Applied

Scientific EffectUbiquitination:

Data Source

PatentUS10155795B2Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same

Publication Date: 2018.12.18 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1α). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.